The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats

Shuanglin Hao, Shue Liu, Xuexing Zheng, Wenwen Zheng, Handong Ouyang, Marina Mata, David J. Fink

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Tolerance and dependence are common complications of long-term treatment of pain with opioids, which substantially limit the long-term use of these drugs. The mechanisms underlying these phenomena are poorly understood. Studies have implicated the midbrain periaqueductal gray (PAG) in the pathogenesis of morphine withdrawal, and recent evidence suggests that proinflammatory cytokines in the PAG may play an important role in morphine withdrawal. Here we report that chronic morphine withdrawal-induced upregulation of glial fibrillary acidic protein (GFAP), tumor necrosis factor alpha (TNFα) and phosphorylation of ERK1/2 (pERK1/2) in the caudal ventrolateral PAG (vlPAG). Microinjection of recombinant TNFα into the vlPAG followed by intraperitoneal naloxone resulted in morphine withdrawal-like behavioral signs, and upregulation of pERK1/2, expression of Fos, and phosphorylation of cAMP response element binding (pCREB) protein. We used a herpes simplex virus (HSV)-based vector expressing p55 soluble TNF receptor (sTNFR) microinjected into the PAG to examine the role of the proinflammatory cytokine TNFα in the PAG in the naloxone-precipitated withdrawal response. Microinjection of HSV vector expressing sTNFR into the PAG before the start of morphine treatment significantly reduced the naloxone-precipitated withdrawal behavioral response and downregulated the expression of GFAP and TNFα in astrocytes of the PAG. TNFR type I colocalized with neuronal pERK1/2. Microinjection of HSV vector expressing sTNFR into the PAG also significantly reduced the phosphorylation of both ERK1/2 and CREB, and reduced Fos immunoreactivity in neurons of the PAG following naloxone-precipitated withdrawal. These results support the concept that proinflammatory cytokines expressed in astrocytes in the PAG may play an important role in the pathogenesis of morphine withdrawal response.

Original languageEnglish
Pages (from-to)664-676
Number of pages13
JournalNeuropsychopharmacology
Volume36
Issue number3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Periaqueductal Gray
Naloxone
Morphine
Tumor Necrosis Factor-alpha
Phosphorylation
Tumor Necrosis Factor Receptors
Microinjections
Simplexvirus
Glial Fibrillary Acidic Protein
Cytokines
Astrocytes
Up-Regulation
Receptors, Tumor Necrosis Factor, Type I
Cyclic AMP Response Element-Binding Protein
Mesencephalon
Opioid Analgesics
Down-Regulation
Neurons
Pain

Keywords

  • gene therapy
  • morphine withdrawal
  • PAG
  • soluble TNF receptor
  • TNFa

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. / Hao, Shuanglin; Liu, Shue; Zheng, Xuexing; Zheng, Wenwen; Ouyang, Handong; Mata, Marina; Fink, David J.

In: Neuropsychopharmacology, Vol. 36, No. 3, 01.02.2011, p. 664-676.

Research output: Contribution to journalArticle

Hao, Shuanglin ; Liu, Shue ; Zheng, Xuexing ; Zheng, Wenwen ; Ouyang, Handong ; Mata, Marina ; Fink, David J. / The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. In: Neuropsychopharmacology. 2011 ; Vol. 36, No. 3. pp. 664-676.
@article{c4bc6a697ff24bffa0f954979b0c11a5,
title = "The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats",
abstract = "Tolerance and dependence are common complications of long-term treatment of pain with opioids, which substantially limit the long-term use of these drugs. The mechanisms underlying these phenomena are poorly understood. Studies have implicated the midbrain periaqueductal gray (PAG) in the pathogenesis of morphine withdrawal, and recent evidence suggests that proinflammatory cytokines in the PAG may play an important role in morphine withdrawal. Here we report that chronic morphine withdrawal-induced upregulation of glial fibrillary acidic protein (GFAP), tumor necrosis factor alpha (TNFα) and phosphorylation of ERK1/2 (pERK1/2) in the caudal ventrolateral PAG (vlPAG). Microinjection of recombinant TNFα into the vlPAG followed by intraperitoneal naloxone resulted in morphine withdrawal-like behavioral signs, and upregulation of pERK1/2, expression of Fos, and phosphorylation of cAMP response element binding (pCREB) protein. We used a herpes simplex virus (HSV)-based vector expressing p55 soluble TNF receptor (sTNFR) microinjected into the PAG to examine the role of the proinflammatory cytokine TNFα in the PAG in the naloxone-precipitated withdrawal response. Microinjection of HSV vector expressing sTNFR into the PAG before the start of morphine treatment significantly reduced the naloxone-precipitated withdrawal behavioral response and downregulated the expression of GFAP and TNFα in astrocytes of the PAG. TNFR type I colocalized with neuronal pERK1/2. Microinjection of HSV vector expressing sTNFR into the PAG also significantly reduced the phosphorylation of both ERK1/2 and CREB, and reduced Fos immunoreactivity in neurons of the PAG following naloxone-precipitated withdrawal. These results support the concept that proinflammatory cytokines expressed in astrocytes in the PAG may play an important role in the pathogenesis of morphine withdrawal response.",
keywords = "gene therapy, morphine withdrawal, PAG, soluble TNF receptor, TNFa",
author = "Shuanglin Hao and Shue Liu and Xuexing Zheng and Wenwen Zheng and Handong Ouyang and Marina Mata and Fink, {David J.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1038/npp.2010.197",
language = "English",
volume = "36",
pages = "664--676",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats

AU - Hao, Shuanglin

AU - Liu, Shue

AU - Zheng, Xuexing

AU - Zheng, Wenwen

AU - Ouyang, Handong

AU - Mata, Marina

AU - Fink, David J.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Tolerance and dependence are common complications of long-term treatment of pain with opioids, which substantially limit the long-term use of these drugs. The mechanisms underlying these phenomena are poorly understood. Studies have implicated the midbrain periaqueductal gray (PAG) in the pathogenesis of morphine withdrawal, and recent evidence suggests that proinflammatory cytokines in the PAG may play an important role in morphine withdrawal. Here we report that chronic morphine withdrawal-induced upregulation of glial fibrillary acidic protein (GFAP), tumor necrosis factor alpha (TNFα) and phosphorylation of ERK1/2 (pERK1/2) in the caudal ventrolateral PAG (vlPAG). Microinjection of recombinant TNFα into the vlPAG followed by intraperitoneal naloxone resulted in morphine withdrawal-like behavioral signs, and upregulation of pERK1/2, expression of Fos, and phosphorylation of cAMP response element binding (pCREB) protein. We used a herpes simplex virus (HSV)-based vector expressing p55 soluble TNF receptor (sTNFR) microinjected into the PAG to examine the role of the proinflammatory cytokine TNFα in the PAG in the naloxone-precipitated withdrawal response. Microinjection of HSV vector expressing sTNFR into the PAG before the start of morphine treatment significantly reduced the naloxone-precipitated withdrawal behavioral response and downregulated the expression of GFAP and TNFα in astrocytes of the PAG. TNFR type I colocalized with neuronal pERK1/2. Microinjection of HSV vector expressing sTNFR into the PAG also significantly reduced the phosphorylation of both ERK1/2 and CREB, and reduced Fos immunoreactivity in neurons of the PAG following naloxone-precipitated withdrawal. These results support the concept that proinflammatory cytokines expressed in astrocytes in the PAG may play an important role in the pathogenesis of morphine withdrawal response.

AB - Tolerance and dependence are common complications of long-term treatment of pain with opioids, which substantially limit the long-term use of these drugs. The mechanisms underlying these phenomena are poorly understood. Studies have implicated the midbrain periaqueductal gray (PAG) in the pathogenesis of morphine withdrawal, and recent evidence suggests that proinflammatory cytokines in the PAG may play an important role in morphine withdrawal. Here we report that chronic morphine withdrawal-induced upregulation of glial fibrillary acidic protein (GFAP), tumor necrosis factor alpha (TNFα) and phosphorylation of ERK1/2 (pERK1/2) in the caudal ventrolateral PAG (vlPAG). Microinjection of recombinant TNFα into the vlPAG followed by intraperitoneal naloxone resulted in morphine withdrawal-like behavioral signs, and upregulation of pERK1/2, expression of Fos, and phosphorylation of cAMP response element binding (pCREB) protein. We used a herpes simplex virus (HSV)-based vector expressing p55 soluble TNF receptor (sTNFR) microinjected into the PAG to examine the role of the proinflammatory cytokine TNFα in the PAG in the naloxone-precipitated withdrawal response. Microinjection of HSV vector expressing sTNFR into the PAG before the start of morphine treatment significantly reduced the naloxone-precipitated withdrawal behavioral response and downregulated the expression of GFAP and TNFα in astrocytes of the PAG. TNFR type I colocalized with neuronal pERK1/2. Microinjection of HSV vector expressing sTNFR into the PAG also significantly reduced the phosphorylation of both ERK1/2 and CREB, and reduced Fos immunoreactivity in neurons of the PAG following naloxone-precipitated withdrawal. These results support the concept that proinflammatory cytokines expressed in astrocytes in the PAG may play an important role in the pathogenesis of morphine withdrawal response.

KW - gene therapy

KW - morphine withdrawal

KW - PAG

KW - soluble TNF receptor

KW - TNFa

UR - http://www.scopus.com/inward/record.url?scp=78651401018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651401018&partnerID=8YFLogxK

U2 - 10.1038/npp.2010.197

DO - 10.1038/npp.2010.197

M3 - Article

VL - 36

SP - 664

EP - 676

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -